Bpifrance

Bpifrance Financement S.A. is a French financial institution that provides a range of financing solutions and support services aimed at fostering the growth of startups, small and medium-sized enterprises (SMEs), and mid-cap companies. It offers various financial products, including medium to long-term loans, export insurance, and leasing options for both tangible and intangible assets. Additionally, Bpifrance supports companies through consulting services, guarantees for bank financing, and training for executives. The organization also engages in direct investments and manages funds aimed at enhancing the financial landscape for businesses at different stages of their development. Established in 1980 and based in Maisons-Alfort, France, Bpifrance was formerly known as OSEO S.A. and rebranded in July 2013. It operates as a subsidiary of Bpifrance SA, reinforcing its commitment to bolstering the French economy through diversified financial solutions.

Focus

Seed Round Early Venture Series A Scale Stage Series B Show more

http://bpifrance.fr

http://www.bpifrance.com

https://crunchbase.com/organization/bpifrance

https://facebook.com/bpifrance

https://linkedin.com/company/bpifrance

https://pitchbook.com/profiles/fund/15720-31F

https://twitter.com/bpifrance

https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=37314358

Céline André

Investment Director

Adonis Arnaud

Junior Investment Manager

Laurent Arthaud

Managing Director

Françis Aymard

Investment Director

Simon Beauroy

Director

Isabelle Bebear

Director for International and University

Soukanda Bentaleb

Investment Officer

Pascal Bordat

Investment Director

Nathalie Carmona

Associate

Yoann Caujolle

Portfolio Director

Nicolas Ceria

Associate

Ménelé Chesnot

Senior Investment Director

Samuel Dalens

Investment Director

Florent Debienne

Managing Director | Head of Technology Funds Investments

Christian Deblaye

Deputy MD

Luc Doyennel

Investment Director

Nicolas Dufourcq

CEO

Jean-Yves Duriez

Investment Director

Antoine Emmanuelli

Partnership Director

Francis Estellat

Senior Investment Director

Alain Fakhoury

Investment Director Bretagne

Stephen Fargis

Associate

Arnaud Fauquembergue

Investment Manager

Olivier Fosse

Investment Director Alsace Champagne-Ardenne Lorraine

Jean-Marie Fougeray

Investment Director Bretagne

Stéphanie Frachet

Investment Director

Ronan Frefield

Portfolio Director

Laurence Gauthier

Senior Investment Director Bourgogne Franche-Comté

Xavier Gelot

Director of Fonds de Renforcement des PME

Emmanuelle Gervais

Senior Investment Director

Isabelle Ginestet-Naudin

Deputy MD and Director of Sectorial Funds

Vanessa Giraud

Managing Director

Alessandro Gonella

Director

José Gonzalo

Executive Director Mid and Large Cap Direction

Alexis Guinard

Investment Director

Raphaël Guterman

Associate

Yonel Génin

Partnership Director

Luc Heinrich

MD

Hubert Hernandez

Investment Director

Hortense Jacon

Investment Associate

Véronique Jacq

Managing Director

Jean-René Jégou

Director of the Regional Funds Department

Pascal Lagarde

Director

Caroline Lebel

Senior Associate

Eric Lefebvre

Director

Ronan Lefort

Investment Director

Arnaud Legardeur

Investment Director

Christian Leonetti

Investment Director

Olivier Levy

Director of East private equity Interregional Network

Cedric Lowenbach

Director of Operations

Arielle Marsaud

Associate

Alex Marvaldi

Partner

Laure Michel

Investment Director

Maud Moulin

Portfolio Director

Sébastien Moynot

Investment Director and Member of the Management Board

Philippe Mutricy

Deputy MD

Valérie de la Ménardière

Investment Director

Alexandre Ossola

MD

Stanislas Panhard

Senior Investment Director

Nicolas Parpex

Senior Investment Director

Sophie Perette

Portfolio Director Alsace Champagne-Ardenne Lorraine

Thibault Peroys

Investment Director

Axel Piriou

Senior Investment Manager

Marc Prévôt

Director of North Private Equity Interregional Network

Matthieu Rabeisen

Portfolio Director

Sarah Roeland

Investment Manager

Stéphane Romang

Investment Director

Thibaut Roulon

Investment Director

Julie Régnier

Senior Investment Manager Alsace Champagne-Ardenne Lorraine

Eduardo Sampaio

Portfolio Director

Nadia Sarri

Investment Director

Gilles Schang

Deputy Managing Director

Nicolas de La Serre

Investment Director Pays de la Loire

Thierry Sommelet

MD

Vincent Stievenard

Investment Director and Director of North Private Equity Interregional Network

Xavier Tessier

Director

Gabrielle Tetart

Senior Investment Manager and Associate

Tuan Tran

Investment Director

Alain Tueux

Investment Director

Stanislas de Tymowski

Associate

Adrien Vasseur

Portfolio Director

Benoît Villain

Senior Investment Manager

Philippe Vuarchex

Associate

Stéphanie Vuillaume

Associate

Romain Vérani

Associate

Samuel Waddell

Associate

Past deals in Grant

Shortcut

Grant in 2022

Saas

Osivax

Grant in 2022

Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.

Susu

Grant in 2022

Susu is a dynamic and innovative company that offers a wide range of health services for families in the African diaspora. Susu provides a complete offer on Preventive care, Medical treatments, Management of chronic diseases, and Authentic drugs.

Signia Therapeutics

Grant in 2022

Signia Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.

Pherecydes Pharma

Grant in 2022

Pherecydes Pharma SA engages in the research and development of lytic bacteriophages for therapeutic and diagnostic applications with a focus on antibiotic resistance. It develops several banks of bacteriophages, including the collection of phages against Escherichia coli. The company was incorporated in 2006 and is based in Romainville, France.

Luos

Grant in 2021

Get rid of electronics struggles thanks to an open source architecture to turn electronics devices and subsets as microservices.

Adeunis

Grant in 2021

Adeunis is a company based in Crolles, France, that specializes in designing, manufacturing, and marketing connected objects and Internet of Things (IoT) solutions for business applications worldwide. The company offers a diverse range of products, including radio frequency transmission modules, wireless transmission systems, and various sensors for temperature and other data readings. Adeunis serves multiple sectors, such as smart buildings, remote energy management, industrial optimization, connected agriculture, and transport. Additionally, the company provides customized radio solutions tailored to specific customer needs. Its services extend to on-site radio mapping, deployment, training, data processing, and sensor maintenance, enabling clients to effectively manage their buildings and operations.

C12 Quantum Electronics

Grant in 2021

C12 Quantum Electronics develop reliable quantum processors with carbon nanotubes. Its unique technology reduces drastically the error rate, making the platform a prime candidate for noisy intermediate-scale quantum applications. The Paris, Ile-de-France, France-based company was formed in 2019 by Pierre and Matthieu Desjardins.

Biophytis

Grant in 2021

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Their goal is to become a leader in the emerging field of aging science by delivering life-changing therapies to the growing number of patients in need that have limited or no treatment options. To accomplish this goal, they have assembled an experienced and skilled group of industry professionals, scientists, clinicians and key opinion leaders from leading industry and academic institutions from around the world.

OncoDiag

Grant in 2021

OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities. The company is focused on developing of non-invasive diagnostic tests for early detection of cancers. Its lead product the Urotest (CE-IVD) is a urine test for diagnosis and surveillance of bladder cancer. The company's pipeline also includes the Colodiag in development for early detection of colorectal cancer.

Luos

Grant in 2021

Get rid of electronics struggles thanks to an open source architecture to turn electronics devices and subsets as microservices.

OSE Immunotherapeutics

Grant in 2020

OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.

bybr

Grant in 2020

ByBr operates a mobile application that facilitates the connection between consumers and brands through a simple interface that allows users to either type or scan brand names or logos. The app provides immediate access to localized official information, including websites, social media links, contact details, and messaging options, allowing for effortless interaction. Additionally, ByBr serves as an online platform for influencer and brand marketing, enabling brands to discover and collaborate with influential creators worldwide. This marketplace streamlines the process of communication and campaign management, while also ensuring secure payment methods for both brands and influencers. ByBr aims to enhance consumer engagement with brands and provide a seamless experience for users and marketers alike.

Multiwave Imaging

Grant in 2020

Multiwave Imaging is a French company recognized as a leader in the design of metamaterial MRI antennas. It operates as a wholly owned subsidiary of Multiwave Technologies AG, which was founded in Switzerland in March 2015 and has its headquarters in Geneva. The company focuses on developing innovative metamaterial technologies aimed at enhancing quality of life. Multiwave Imaging's primary objective is to create and harness intellectual property, assess its commercial viability, and establish management teams to transform these innovations into marketable products. This strategic approach enables Multiwave Imaging to build companies across various sectors, leveraging advanced technology to address diverse needs.

Osivax

Grant in 2020

Xenothera

Grant in 2020

Xenothera SAS, a biotechnology company, develops a platform with embedded technology that renovates immunological treatments. It develops new therapeutic modes in various domains from immunomodulation to infectious diseases. It addresses unmet medical needs with proprietary Glyco-Humanized Antibodies. The company’s therapeutic modes are based on animal genetics and mastery of immunology processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera. Xenothera SAS was incorporated in 2014 and is based in Nantes, France.

Quantum Surgical

Grant in 2020

Quantum Surgical is a provider of surgical robotics focused on developing innovative solutions for minimally invasive surgeries. The company is creating a novel robotic platform designed to enhance the assessment, planning, and treatment of medical conditions. Its technology supports advanced percutaneous ablation therapy, particularly for liver cancer treatment, aiming to improve patient outcomes and enhance the safety of interventional oncology procedures. With a commitment to delivering effective clinical solutions, Quantum Surgical seeks to represent unique spinal products and treatment options, benefiting both physicians and patients throughout the continuum of care.

Multiwave Imaging

Grant in 2020

Vulkam

Grant in 2020

Vulkam SAS, a micro technology company, engages in the design, development, and production of amorphous metal parts. The company’s amorphous metals are primarily composed of zirconium, copper, hafnium, nickel, or titanium. Its products have applications in aerospace, automotive, biomedical, cryogenic, watches, jewellery, micro components, and micro fluids industries. Vulkam SAS was founded in 2017 and is based in Saint-Martin-d'Hères, France.

TreeFrog Therapeutics

Grant in 2019

TreeFrog Therapeutics is a stem cell company based in Pessac, France, founded in 2018. It focuses on researching and producing scalable stem cell cultivation for cGMP cell therapy manufacturing. The company has developed C-Stem, a proprietary technology platform that offers an end-to-end 3D scalable solution, aimed at securing cell production and quality. This innovative approach is designed to expedite clinical development and facilitate market access for cell therapies. By addressing critical manufacturing challenges, TreeFrog Therapeutics aims to significantly reduce treatment costs, making advanced cell therapies more accessible to patients.

ImCheck Therapeutics

Grant in 2019

ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.

PECULIUM

Grant in 2019

Peculium is a transparent, savings platform based on automatic machine learning.

Skipper NDT

Grant in 2019

SKIPPER NDT is the solution for improving the integrity of unpiggable pipelines. The continuous R&D efforts deployed by SKIPPER NDT allow us to boost the performance of the technology and extend the field of application, also to offshore pipelines.

TreeFrog Therapeutics

Grant in 2019

Alkion BioInnovations

Grant in 2019

In 2011, Alkion BioPharma has been created to revolutionize the secondary metabolims production for cancer therapies. Imperial Innovations, a team of Imperial College researchers and business professionals joined together to develop the technologies able to transform the non-GMO plants into a natural biorefinery. Quickly the technological platform received strong interests from the cosmetic community and the company signed research contracts to develop new disruptive cosmetic ingredients. Four years after inception, with a strong commercial pipeline, Alkion BioPharma has been acquired by Evonik Industries AG for cosmetic & food supplements applications. The new company Alkion BioInnovations was created in March 2017 in order to develop disruptive nutrition, non-cosmetic oil, and agrochemical solutions. The company owns exclusive rights on this applications.

Ascendance Flight Technologies

Grant in 2019

At Ascendance we are building tomorrow’s flying taxi: Atea, a unique Vertical Take-Off and Landing (VTOL) aircraft with a hybrid propulsion system. We believe that the future of mobility will include the sky and that operational fit will be key to support the emergence of this market. Therefore we focused our efforts in designing an innovative, safe, silent, clean and affordable aircraft that will be able to blend into existing infrastructures and regulations to ease its deployment and maximise social acceptance.

Capte

Grant in 2018

Capte develops, produces and integrates smart IOT solutions for transportation.

DNA Script

Grant in 2018

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

DNA Script

Grant in 2018

Eversend

Grant in 2017

Eversend SAS, founded in 2017 and based in Paris, France, offers a multi-currency e-wallet application that enables users to send and receive money, buy cryptocurrency, create virtual cards, and purchase airtime. The platform leverages blockchain technology to provide a digital payment gateway, facilitating electronic money transfers to bank accounts and mobile payments while minimizing costs associated with fees and foreign exchange. In addition to its current services, Eversend plans to expand its offerings to include personal loans, savings, group savings, merchant payments, and investment options. The company aims to grow its presence in Nigeria, Francophone Africa, and Europe while utilizing funds for product development, user acquisition, and regulatory compliance.

OSE Immunotherapeutics

Grant in 2017

Internest

Grant in 2017

Internest is a developer of a precise positioning system designed for rotating winged vehicles. The company's system utilizes a local landing system which is an embedded system with firmware and hardware to provide robust and accurate positioning information for all visibility, weather and environment, enabling security companies, military and maritime companies to assist drones and helicopters in their critical operations to improve flight safety.

VeriCampus

Grant in 2017

VeriCampus enables College/Universities to provide personalized student support at scale, utilizing Artificial Intelligence. We develop AI-powered ‘Campus Assistant’ Chatbots that take on the character and knowledgebase of the institution, helping students successfully navigate through college.

Conscious Labs

Grant in 2016

Bringing Empathy to Human-Tech Interactions

Seamless Waves

Grant in 2016

Seamless Waves is a company specialized in the design and implementation of reconfigurable RF transceivers. These transceivers are capable of sweeping the frequency spectrum, identifying the least occupied frequency band and then establishing a communication using the wireless standard adapted to this band. Thanks to their highly efficient RF Analog-to-Digital converters, these transceivers achieve a very low power consumption that is well suited for portable devices. Seamless Waves is also a provider of silicon-proven Analog/RF Physical IPs and their virtual component models that can be used for early system integration.

Alkion BioInnovations

Grant in 2016

Omind Neurotechnologies

Grant in 2016

Omind Neurotechnologies, founded in 2016 and based in Paris, France, specializes in developing neuro-technologies aimed at enhancing brain plasticity to better adapt to contemporary life. The company focuses on creating applications that facilitate the tracking, measurement, and training of brain functions, with an emphasis on emotional management, cognitive performance, and self-awareness. Its offerings include stress assessment tools, personalized analysis, and stress management training delivered in a virtual reality setting. Additionally, Omind develops neurotraining services, a normative multimodal database, and platforms that support real-time multimodal signal processing. The team comprises 19 members, including nine Ph.D. holders, who contribute to the company's intellectual property, trade secrets, and open science publications in the field of neurotechnology.

Polywed

Grant in 2016

Polywed is a Healthcare IT company developing the data-driven technology that increases in vitro fertilization (IVF) success rates. Today average IVF live birth rate is about 30%. BioChron technology doubles the efficiency of the treatment up to 60%.

Connected Cycle

Grant in 2015

Connected Cycle offers innovative and cost-effective geolocation solutions tailored for both bikes and industrial assets. Full range portfolio from sensor to fleet management platform.

Ledger

Grant in 2015

Ledger develops security and infrastructure solutions for cryptocurrencies as well as blockchain applications for individuals and companies, by leveraging a distinctive, proprietary technology. Launched in 2014, Ledger has designed an acclaimed line of hardware security devices quickly placing the company as a global leader on the market with 1,000,000 units sold in more than 165 countries. For enterprises and corporations, Ledger introduced the Vault: a fully managed SaaS solution addressing the need to safeguard a very large amount of multiple cryptocurrencies while mitigating both IT and physical assault threats. The company is also active on the industrial IoT market, leveraging its secure hardware technology to interface sensors and machines to smart contracts or blockchain based assets. Ledger is headquartered in Paris, has a production facility in Vierzon (France) and offices in San Francisco.

Q°emotion

Grant in 2015

Q°emotion is an emotional and semantic solution for analysing the opinions of your customers and employees. Their SaaS platform detects the emotions and sensations felt to provide insights and improve experience.

Antabio

Grant in 2015

Antabio SAS develops drugs that block the virulence of bacteria. It offers molecules for the treatment of antibiotics resistant nosocomial infections. The company develops and MBLi: Metallo Beta-Lactamase inhibitor, an inhibitor of bacterial MBLs; discovered SBLi: Serine Beta-Lactamase inhibitor, SBL inhibitor with broad coverage against key SBL enzymes, including ESBLs, KPC and OXA-type carbapenemases in Enterobacteriaceae and Acinetobacter baumannii; and PEi : Pseudomonas Elastase inhibitors (powered by CARB-X), an inhaled drug which can be used as an adjunct to existing antibiotic therapy and which will reduce the frequency and severity of Pseudomonas exacerbations by targeting the three corner-stones of Pseudomonas pathogenesis: virulence, stealthiness and persistence. Antabio SAS was founded in 2009 and is based in Labège, France.

Magnisense

Grant in 2015

Magnisense conçoit, développe et commercialise des tests de diagnostic d'urgence pour les maladies cardio-vasculaires à partir de sa technologie MIAtek® et de son instrument de diagnostic propriétaires

Theravectys

Grant in 2015

Theravectys is a development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Their first clinical studies will be in HIV/AIDS, using their lead product, a therapeutic vaccine, which has shown promising efficacy and safety in non-human primates.

Connected Cycle

Grant in 2014

Connected Cycle offers innovative and cost-effective geolocation solutions tailored for both bikes and industrial assets. Full range portfolio from sensor to fleet management platform.

Antabio

Grant in 2013

Nanobiotix

Grant in 2013

Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.